# KPV Peptide: No Human Trials, and an FDA Panel Recommended It Anyway

> Educational article from Veracue Labs. It summarizes published laboratory research and is not medical advice or instructions for use in people or animals.

- Page: https://veracuelabs.com/blog/kpv-peptide-research-guide
- Author: Veracue Research Team
- Published: 2026-10-30
- Last updated: 2026-10-29
- Topic: Recovery protocols

KPV has never been tested in a published human trial, but in July 2026, an FDA panel voted to recommend it for compounding anyway. This guide separates what cell and mouse studies actually show from what the FDA vote does and doesn't mean.

Key points:
- KPV (Lys-Pro-Val) is the C-terminal tripeptide, residues 11, 13, of the 13-amino-acid hormone α-MSH, and it lacks the hormone's melanocortin core sequence.
- Reference identifiers for the free acid are C16H30N4O4, 342.44 g/mol average mass and CAS 67727-97-3; amide, acetylated and salt forms have different masses.
- Three mechanism leads exist (PepT1 uptake, IL-1β-related signaling, MC1R-independent effects), but they come from different experimental systems and are not a single established pathway.
- All reported KPV findings are preclinical (cell lines, human-derived cell cultures and mice); no human clinical trial of the tripeptide was found in PubMed.
- In July 2026, an FDA advisory panel voted 8, 6 to recommend KPV for 503A compounding despite zero human trials, a non-binding vote, not an approval.
- KPV and KdPT are different molecules, and no universal or human dosage exists; research concentrations are specific to each protocol.
- HPLC purity does not prove identity, and intact mass does not prove sequence or stereochemistry; lot-specific documentation is the only way to characterize a batch.

KPV peptide is a short fragment of the hormone α-melanocyte-stimulating hormone (α-MSH): a tripeptide built from lysine, proline and valine (Lys-Pro-Val, or K-P-V) that matches residues 11, 13 at the C-terminal end of the 13-amino-acid hormone [1][3]. In the laboratory, KPV is used mainly as an experimental tool for questions about inflammatory signaling, peptide transport and intestinal biology, almost always in cell cultures and mice.

Part of the interest is practical. The short half-life and pigmentary side effects of full-length α-MSH were cited as reasons to study its C-terminal tripeptide instead [13], and a review describes KPV as retaining anti-inflammatory effects while lacking the hormone's pigment-inducing activity [12]. Whether KPV does what those reports suggest, and through which mechanism, is still being worked out. A PubMed search run for this guide found no human clinical trial of the KPV tripeptide, so everything below is preclinical evidence, and we label it that way.

Veracue Labs supplies KPV as a Research Use Only (RUO) material. Nothing in this article is guidance for human or veterinary use.

### What Is KPV Peptide?

KPV peptide is a short fragment of the hormone α-melanocyte-stimulating hormone (α-MSH): a tripeptide built from lysine, proline and valine (Lys-Pro-Val, or K-P-V) that matches residues 11, 13 at the C-terminal end of the 13-amino-acid hormone [1][3]. In the laboratory, KPV is used mainly as an experimental tool for questions about inflammatory signaling, peptide transport and intestinal biology, almost always in cell cultures and mice.

### What Is KPV Made Of? Molecular Structure and Sequence

KPV has three residues and two peptide bonds: L-lysine at the N-terminus, L-proline in the middle and L-valine at the C-terminus. Order matters. A search for "kvp" is a common typo, but Lys-Val-Pro or Val-Pro-Lys would be different molecules that happen to contain the same three amino acids and share the same mass.

The reference identifiers for the free-acid form are:

Attribute | Reference value
Sequence | Lys-Pro-Val (K-P-V)
Length | 3 amino acids
Molecular formula | C16H30N4O4
Average molecular weight | 342.44 g/mol
Monoisotopic mass | 342.2267 Da
CAS number | 67727-97-3 (as listed on the Veracue Labs product page)

The formula follows directly from the residues: lysine, proline and valine joined by two peptide bonds lose two molecules of water. Both mass values in the table were recalculated from that formula for this guide. Veracue Labs lists this material as a 10 mg research-grade KPV peptide, identity-confirmed by mass spectrometry.

Common mix-up: "one CAS number means one chemical form." It does not. Chemical catalogs file the free acid and its acetate salt under the same CAS entry, so the number identifies the peptide family rather than the exact form in a vial. A batch's chemical form has to be confirmed on its own documentation.

### How Does KPV Differ From Alpha-MSH?

α-MSH is a 13-residue hormone. Its central core, His-Phe-Arg-Trp at positions 6, 9, is the melanocortin "message" sequence [9], and the hormone signals by binding melanocortin receptors such as MC1R [5]. KPV contains none of that core. It is only the last three residues.

Feature | α-MSH | KPV (α-MSH 11, 13)
Length | 13 amino acids | 3 amino acids
Approximate mass | about 1.66 kDa | 342.44 g/mol
Contains the His-Phe-Arg-Trp core | Yes (positions 6, 9) | No
Melanocortin receptor activity | Binds MC1R [5] | Not detected in binding and cAMP assays in some studies [4]
Pigment-inducing activity | Yes [12][13] | Reported to be absent [12]

Common mix-up: "KPV does what α-MSH does." Findings on the whole hormone cannot be transferred to the fragment. In a mouse peritonitis study, the whole hormone and a synthetic melanocortin agonist suppressed macrophage activation in vitro while KPV did not, and the authors concluded that KPV's anti-inflammatory effect is clearly different from that of the core MSH peptides [3]. Each claim needs evidence generated with KPV itself.

### How Does KPV Work? Understanding Proposed Mechanisms

The KPV mechanism of action is not settled. The literature offers several partial explanations that come from different experimental systems. They are best read as separate leads, not one finished pathway.

#### PepT1-mediated transport

PepT1 is a transporter for di- and tripeptides that is normally found in the small intestine and is induced in the colon during inflammatory bowel disease. Dalmasso and colleagues reported that KPV is taken up by PepT1 in human intestinal epithelial cell lines and in a human T-cell line, and that nanomolar concentrations reduced NF-κB and MAP kinase signaling and cytokine secretion [1]. This is a finding about how KPV can enter certain cells.

Common mix-up: "PepT1 uptake proves a benefit." Transport only shows that the peptide can get in. A later mouse study found that PepT1 overexpression increased colitis-associated tumor burden, and that KPV reduced tumorigenesis in normal mice but not in PepT1-knockout mice [8]. Entry through PepT1 is a necessary step in that model, and the same transporter's upregulation was itself linked to worse outcomes. Neither point is a demonstrated human benefit.

#### IL-1β-related signaling

Getting and colleagues found that KPV reduced neutrophil accumulation in mouse peritonitis and was also active in IL-1β-induced inflammation, while it failed to block macrophage IL-1β release in vitro. They proposed that KPV more likely acts by interfering with IL-1β function than through melanocortin receptors [3]. That is a hypothesis built on indirect evidence. It has not been shown that KPV binds the IL-1 receptor, and a related tripeptide, KdPT, has produced conflicting results on the same question (see below).

Common mix-up: "every proposed anti-inflammatory mechanism for KPV is established." The NF-κB and MAP kinase findings are measurements in specific cell systems, and the IL-1β idea is an inference. Treating them as one confirmed pathway goes beyond what the papers show.

#### The MC1R question

MC1R is the melanocortin receptor most associated with α-MSH. The evidence on KPV is mixed:

- In mice with a nonfunctional MC1R, KPV still protected against colitis, which the authors described as at least partially independent of MC1R [2].
- KPV analogues did not bind melanocortin receptors or raise cAMP in the macrophage and melanoma cell assays used, although they did reduce nitric oxide production, which the authors attributed to a distinct, unidentified site [4].
- In human keratinocyte cultures, KPV did not raise cAMP, but it did trigger calcium signals under certain conditions, including in cells engineered to express MC1R [5].

Common mix-up: "MC1R research explains KPV." MC1R work is relevant background, but the KPV-specific data say MC1R is probably not the whole story, and one cell system points the other way. The mechanism is still incompletely understood.

### What Are KPV Peptide Benefits According to Research?

Searches for "KPV benefits" and "KPV peptide benefits" dominate the keyword data for this topic, so it is worth being precise about what the experiments measured. The table sorts each research area by model and strength of evidence.

Research area | Model | What was measured | Evidence level
Intestinal inflammation | Human intestinal epithelial and T-cell lines; mouse colitis models [1][2] | NF-κB/MAPK signaling, cytokines, weight loss, histology | In vitro and animal
Colitis-associated tumorigenesis | Genetically modified mice [8] | Tumor number and size | Animal
Targeted delivery | Nanoparticle/hydrogel systems in cells and mice [6][7][14] | Retention in inflamed tissue, inflammation scores | In vitro and animal
Skin cell signaling | Human keratinocyte cultures [5] | cAMP, intracellular calcium | In vitro (human cells)
Brain injury | Mouse trauma model [13] | Inflammation and apoptosis markers | Animal

Common mix-up: "Animal results mean human results." Every row above is preclinical. Research in human-derived cell lines is also not a clinical trial; it is cell culture. None of these studies establishes that KPV works, or is safe, in people.

#### KPV and inflammatory signaling research

In the cell work, the consistent observation is reduced pro-inflammatory signaling after KPV exposure, specifically lower NF-κB and MAP kinase activation and fewer secreted cytokines in stimulated epithelial and T cells [1]. In animals, KPV reduced inflammatory infiltrates and myeloperoxidase activity in two colitis models [2]. These are measurements of inflammatory markers in experimental systems. They are not treatment outcomes.

#### KPV and intestinal research

The colitis studies use chemically induced (DSS, TNBS) or T-cell transfer models in mice [1][2]. Several groups then asked whether delivery matters. Laroui and colleagues packaged KPV in nanoparticles inside an alginate-chitosan hydrogel and reported similar protection in DSS colitis at a concentration about 12,000-fold lower than free KPV in solution [6]. A hyaluronic acid-functionalized version in a hydrogel outperformed a version without hyaluronic acid in mice, with effects on mucosal healing and TNF-α [7]. KPV has also been built into nanoparticles as a PepT1-targeting ligand for carrying another compound (cyclosporine A), with improvements reported in a mouse colitis model [14].

These are formulation experiments in animals, and they show how sensitive the results are to the delivery system. What they do not show is demonstrated gastrointestinal benefit in humans.

### How Does KPV Differ From KdPT?

KdPT (Lys-D-Pro-Thr) is often mentioned alongside KPV, but the two are not interchangeable. KdPT swaps valine for threonine and replaces L-proline with its mirror image, D-proline. Reviewers describe it as a derivative that contains the 193, 195 sequence of interleukin-1β [12].

Feature | KPV | KdPT
Sequence | Lys-Pro-Val | Lys-D-Pro-Thr
Third residue | Valine | Threonine
Proline configuration | L-Pro | D-Pro
Formula / average mass | C16H30N4O4 / 342.44 | C15H28N4O5 / 344.41 (calculated)
Origin as described in the literature | C-terminal α-MSH fragment [1] | α-MSH-related, IL-1β 193, 195 sequence [12]
Representative models | Intestinal cells, mouse colitis [1][2] | Human sebocyte line, mouse colitis [10][11]

Common mix-up: "KPV and KdPT are the same thing." They are different molecules with different published datasets, and KdPT's results are not a stand-in for KPV's. KdPT did not bind MC-1R and suppressed IL-1β signaling in a human sebocyte line, with modeling that predicted contact with the IL-1 receptor [11]. In mouse colitis, however, it acted independently of the type I IL-1 receptor [10]. Even within one compound the mechanism is unsettled.

### What Does Research Say About KPV Dosage?

"KPV dosage" and "KPV peptide dosage" appear repeatedly in the keyword workbook, and the honest answer is that no universal figure exists. Reported concentrations depend on the experimental system, the form of the compound, the delivery vehicle and the endpoint measured. Dalmasso and colleagues reported effects at nanomolar concentrations in cell culture [1], while a nanoparticle format in a later study matched the effect of free peptide at a concentration about 12,000-fold lower [6]. Numbers from one setup cannot be carried into another.

Common mix-up: "KPV has an established human dose." It does not. Without human clinical trials, there is no validated human dosing, schedule or safety profile, and this article does not offer one. Researchers working with KPV in vitro should take concentrations from the specific published protocol that matches their model, and treat them as protocol-specific.

### What Are the Limitations of KPV Research?

- Model dependence. Most positive findings come from a few model systems (DSS/TNBS colitis, selected cell lines), and several come from overlapping research groups.
- Mechanism. PepT1 transport, IL-1β interference and MC1R-independent effects have not been tied together experimentally.
- Chemical forms. Papers use different forms (free peptide, acetylated or amidated analogues, formulated particles), and results do not automatically transfer between them.
- Delivery. Efficacy in animals shifts strongly with the delivery system.
- Clinical evidence. No human trial of the KPV tripeptide was found in PubMed.
- Regulatory context. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee considered KPV-related bulk drug substances (KPV free base and KPV acetate) for possible inclusion on the 503A Bulks List. The committee voted 8, 6, with one abstention, to recommend KPV, reportedly over its own career staff's objection that the evidence did not support the move. Advisory-committee recommendations are non-binding: this vote was not FDA approval, does not establish safety or efficacy, and does not by itself place KPV on the 503A list or authorize compounding. See the FDA meeting page and the BMJ report.

### What Is the KPV Molecular Weight, and How Is It Verified?

The KPV molecular weight of 342.44 g/mol applies to the free acid. Other forms differ:

Form | Formula | Average mass (calculated)
Free acid (H-KPV-OH) | C16H30N4O4 | 342.44
C-terminal amide (H-KPV-NH2) | C16H31N5O3 | 341.46
N-acetyl, C-terminal amide (Ac-KPV-NH2) | C18H33N5O4 | 383.49
Acetate salt | free acid plus acetic acid (60.05) per equivalent | counter-ion amount varies by lot

Common mix-up: "all KPV forms have the same molecular weight." They do not, and the amidated form is more than a labeling detail. In native α-MSH the C-terminus is amidated, while chemical databases and the Veracue Labs reference data describe the free acid. Which form a study used is therefore part of reading it.

Analytical methods answer different questions:

- HPLC separates a sample by chemistry and reports the share of the detected signal in the main peak. Because KPV has no aromatic side chains, detection relies on the peptide bond at low UV wavelengths, where buffers and counter-ions can also absorb.
- Mass spectrometry measures mass. For KPV the protonated ion appears near m/z 343.23.

Common mix-up: "high HPLC purity proves identity." A clean single peak says the sample is chromatographically uniform, not that the peak is KPV. Identity needs mass and, ideally, a reference comparison.

Common mix-up: "the right intact mass proves the sequence." Peptides with the same composition share a mass. KPV and a sequence isomer such as VPK, or a stereoisomer containing D-valine (studied in the literature [4][5]), would all give the same intact mass. Telling them apart needs MS/MS fragmentation, comparison with a reference standard, or chiral analysis, depending on the research question.

Finally, the weight on a vial is not necessarily the weight of peptide. Water, counter-ions and other components make up part of a lyophilized powder, so peptide content is a separate measurement.

### How Should You Evaluate KPV Research Material?

A researcher comparing KPV peptides from different suppliers, or assessing any single KPV research peptide, can work through this checklist:

1. Full sequence written out (Lys-Pro-Val) with stereochemistry stated.
2. Chemical form: free acid, amide, acetylated or salt.
3. CAS and formula consistent with that form.
4. Lot number on every document, including the certificate of analysis (COA) itself.
5. HPLC chromatogram, not only a percentage, with method details.
6. Mass spectrometry result that states the ion observed.
7. Testing date and laboratory.
8. Sequence and stereochemistry confirmation where the experiment depends on it (MS/MS, chiral analysis, reference standard).
9. Peptide content if exact quantities matter.

Common mix-up: "a supplier's general statement describes my batch." A product-page line about methods is not a result. Only lot-specific documentation can characterize the material you actually receive.

Explore Veracue Labs' KPV research product for its listed specifications and available lot documentation. The page lists a 10 mg vial (SKU KPV-10MG), HPLC as the purity method and mass spectrometry as the identity method, with lot documentation available on request through the contact page. It is supplied for laboratory research only.

### Conclusion

KPV is a small, well-defined tripeptide with a real but narrow body of evidence: reduced inflammatory signaling in cell lines, protective effects in mouse colitis models, and a transporter (PepT1) that helps explain how it can enter cells. It is not α-MSH, it is not KdPT, and its mechanism is not settled. The gaps matter more than the headlines: no human trials, strong dependence on formulation, and mixed data on MC1R.

For researchers, the practical path is to read primary papers carefully, match the chemical form to the study, and insist on lot-specific analytical documentation. Veracue Labs' KPV research product page lists its specifications for that purpose, strictly for laboratory use. See also the medical disclaimer and the certificates page.

### Research Use Only Disclaimer

> Research Use Only (RUO): KPV supplied by Veracue Labs is intended strictly for laboratory research and scientific investigation. It is not intended for human or veterinary consumption, ingestion, injection, inhalation, or any form of administration. This article is provided for educational and scientific research purposes only and does not constitute medical advice. Research findings do not establish clinical safety or efficacy. The product has not been evaluated or approved by the FDA for diagnosis, treatment, cure, or prevention of any disease.

Questions and answers:

Q: What is KPV peptide?
A: KPV peptide is a three-amino-acid fragment, Lys-Pro-Val, that matches residues 11, 13 at the C-terminal end of α-melanocyte-stimulating hormone (α-MSH). It is studied in laboratories as a tool for inflammatory-signaling, peptide-transport and intestinal-biology research, mostly in cell cultures and mice. No human clinical trial of the tripeptide was found in PubMed.

Q: What are the three amino acids in KPV?
A: KPV is made of L-lysine (K), L-proline (P) and L-valine (V), joined in that order from the N-terminus to the C-terminus. The order matters: other arrangements of the same three amino acids are different molecules, and a version containing a D-amino acid is a stereoisomer with the same mass but a different structure.

Q: What is KPV peptide used for in research?
A: In published research, KPV is used as an experimental anti-inflammatory fragment in cell-culture and mouse colitis models, as a substrate for studying the PepT1 di- and tripeptide transporter, and as a targeting ligand in nanoparticle delivery studies. These are laboratory applications, not established clinical uses.

Q: What are the proposed KPV peptide benefits?
A: Proposed benefits come from preclinical work: reduced NF-κB and MAP kinase signaling and cytokine release in cell lines, and less inflammation in mouse colitis models. Other areas include delivery-system studies and skin or brain models. These are laboratory observations, and none has been shown to translate into clinical benefit in people.

Q: How does KPV differ from alpha-MSH?
A: α-MSH is a 13-amino-acid hormone with a His-Phe-Arg-Trp core that signals through melanocortin receptors and affects pigmentation. KPV is only its last three residues, lacks that core, and has been reported to lack pigment-inducing activity. Results from the whole hormone should not be assumed to apply to KPV.

Q: What is the molecular weight of KPV?
A: The average molecular weight of KPV free acid (C16H30N4O4) is 342.44 g/mol, with a monoisotopic mass of 342.2267 Da. Amidated, acetylated or salt forms have different masses; the C-terminal amide, for example, is about 341.46 g/mol. Always confirm the chemical form on lot-specific documentation.

Q: What is the CAS number for KPV?
A: The CAS number listed for KPV (Lys-Pro-Val) is 67727-97-3. Chemical catalogs file both the free acid and its acetate salt under this number, so it identifies the peptide family and not necessarily the exact form in a given batch. Confirm the chemical form on lot-specific documentation.

Q: What is the difference between KPV and KdPT?
A: KdPT is Lys-D-Pro-Thr: threonine replaces valine and D-proline replaces L-proline. It is described as containing the 193, 195 sequence of interleukin-1β and has its own datasets, including a sebocyte study and mouse colitis work. It is a different molecule with a different mass (about 344.41 g/mol), so findings should not be interchanged.

Q: What does research say about KPV dosage?
A: No universal KPV dosage exists, and there is no validated human dosing because no human clinical trial of the tripeptide was found. Research concentrations vary with the experimental system, compound form, delivery vehicle and endpoint; one study reported a nanoparticle format matching free peptide at a roughly 12,000-fold lower concentration. This article gives no dosing guidance.

Q: How can researchers evaluate KPV identity and purity?
A: Ask for lot-specific documentation: the full sequence and chemical form, an HPLC chromatogram for chromatographic purity, and a mass spectrometry result for identity. HPLC purity does not prove identity, and intact mass does not prove sequence or stereochemistry, so MS/MS, a reference standard or chiral analysis may also be needed. Peptide content should be stated separately from powder weight.

References:
1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. (https://doi.org/10.1053/j.gastro.2007.10.026)
2. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. (https://doi.org/10.1002/ibd.20334)
3. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-7. (https://doi.org/10.1124/jpet.103.051623)
4. Muceniece R, Krigere L, Süli-Vargha H, Wikberg JE. Effects of alpha-melanotropin C-terminal tripeptide analogues on macrophage NO production. Peptides. 2003;24(5):701-7. (https://doi.org/10.1016/s0196-9781(03)00128-1)
5. Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004;122(4):1010-9. (https://doi.org/10.1111/j.0022-202X.2004.22404.x)
6. Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843-53. (https://doi.org/10.1053/j.gastro.2009.11.003)
7. Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-40. (https://doi.org/10.1016/j.ymthe.2016.11.020)
8. Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-57. (https://doi.org/10.1016/j.jcmgh.2016.01.006)
9. Carotenuto A, Saviello MR, Auriemma L, et al. Structure-function relationships and conformational properties of alpha-MSH(6-13) analogues with candidacidal activity. Chem Biol Drug Des. 2007;69(1):68-74. (https://doi.org/10.1111/j.1747-0285.2007.00473.x)
10. Bettenworth D, Buyse M, Böhm M, et al. The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function. Am J Pathol. 2011;179(3):1230-42. (https://doi.org/10.1016/j.ajpath.2011.05.013)
11. Mastrofrancesco A, Kokot A, Eberle A, et al. KdPT, a tripeptide derivative of alpha-melanocyte-stimulating hormone, suppresses IL-1 beta-mediated cytokine expression and signaling in human sebocytes. J Immunol. 2010;185(3):1903-11. (https://doi.org/10.4049/jimmunol.0902298)
12. Böhm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Exp Dermatol. 2019;28(3):219-24. (https://doi.org/10.1111/exd.13887)
13. Schaible EV, Steinsträßer A, Jahn-Eimermacher A, et al. Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. PLoS One. 2013;8(8):e71056. (https://doi.org/10.1371/journal.pone.0071056)
14. Wu Y, Sun M, Wang D, et al. A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis. Biomater Sci. 2019;7(10):4299-309. (https://doi.org/10.1039/c9bm00925f)

More from Veracue Labs: https://veracuelabs.com/llms.txt